Comprehensive Autism Screening Program (CAS)
The Hong Kong Developmental Paediatrics and Child Neurology Centre's Comprehensive Autism Screening (CAS) program determines Autism Spectrum disorder risk.
​
The test is tailor-made for infants and young children 18 months or younger with a family history of Autism Spectrum Disorder (ASD) and for premature babies.
As Autism is highly heritable, with genetic factors contributing 40 to 80 percent of the risk, these children are at elevated risks of developing ASD and its comorbidities.
​
The CAS program uses non-invasive neural encoding, whole genome sequencing, and clinical assessment to determine ASD risks.
​
Early diagnosis enables timely treatment of ASD with improved outcomes.
The program includes the following testing, assessment, and counseling
​
EEG (Electroencephalogram) is a simple, non-invasive procedure by placing electrodes on the child’s head to detect signals produced by the brain.
The test determines the risk of language deficit, an early sign of Autism Spectrum Disorder
Clinical whole genome sequencing is a non-invasive genetic test analyzing over 20,000 genes and 3 billion base pairs in the entire human genome.
The test detects genetic mutations associated with Autism Spectrum Disorder, and its co-occurring conditions, also known as comorbidity, including speech delay, intellectual disability, developmental regression, movement disorder, and seizures.
Clinical assessment will be provided by a physician specialist in developmental-behavioural paediatrics.
Genetic counseling will be provided by a board-eligible genetic counselor.
Test Process
Whole genome sequencing is performed at a U.S. CAP-accredited and CLIA-certified Laboratory.
Clinical report (English) is issued by a board-certified medical director (Dual M.D. & Ph.D).
Patient data and privacy is protected by the laboratory’s U.S. HIPPA-compliant testing process.
Neural encoding EEG is performed at the Hong Kong Developmental Paediatrics and Child Neurology Centre.
​